Loading…

Virbac SAVIRP.PACompetitor analysis, valuation and peers

France · EUR·Health Care›Biotechnology

Develops and sells veterinary medicines and pet/livestock health products worldwide.

Momentum strong 69
Mkt cap
$3.20B
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$1.80M
20-day average traded
Fwd P/E
16.6×
forward earnings
ROIC−WACC
+3.4 pp
WACC 8.5%
Hurdle
-4 pp
Req g minus delivered
Next earnings
125 days
23 Mar 2027
Close · EUR€348.00
1D-0.8%
1W-2.8%
1M+0.9%
3M+4.8%
6M-4.3%
YTD-2.7%
1Y-2.4%
ATR %2.0%
52w lowhigh10.7% off high

What Virbac does

Develops and sells veterinary medicines and pet/livestock health products worldwide.

Sells prescription and over-the-counter animal medicines through distributors, and vets decide what pet owners buy, so relationships with vets drive sales. Companion-animal products, such as vaccines and parasite treatments, carry more weight than livestock products, and sales spread across Europe, Asia-Pacific and the US.

Products and services

  • Companion animal medicines (vaccines, parasiticides)
  • Livestock/farm animal health products
  • Diagnostics

Customers

  • Veterinarians and animal health distributors globa

Where it sits in the supply chain

  • Healthcare
  • Animal health pharmaceuticals
  • Companion animal + livestock veterinary…

What could go right

  • Pet ownership/pet health spending growth
  • Livestock health demand in emerging markets

What could go wrong

  • Generic veterinary drug competition
  • Regulatory approval timelines/costs

Moat: narrow (IP / patents, regulatory licence, distribution). Regulatory approvals and established veterinary distribution relationships create moderate barriers to entry.

Headquarters: Carros, France · Founded: 1968 · Employees: 6,442

Named competitors

Virbac at a glance

Size Virbac (VIRP.PA) is a France Health Care company (Biotechnology) with a market value of $3.20B, the 83rd largest of 206 France companies the cockpit tracks. Shares closed at €348.00 on 18 Nov 2026.

Performance Over six months the shares fell 4.3%, against +5.5% for the median peer and -2.1% for the France market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue grew 4.3% over the last twelve months (peer median +8.9%); the operating margin is 15.1% (peer median -3.2%).

Valuation It trades at 16.6× forward earnings against a peer median of 31.3× (2nd cheapest of 9).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.4 points above its cost of capital (8.5% WACC).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 104VIRP.PA 96
Six months, rebased to 100: Virbac against the median of its 20 peers (local-currency closes).

Virbac financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€1.49B€1.46B€1.40B€1.25B€1.22B
Revenue growth—+5%+12%+3%—
Gross profit€532M€518M€501M€423M€427M
EBITDA€289M€277M€275M€220M€219M
Net income€156M€151M€145M€121M€122M
Free cash flow€127M€103M€131M€77.9M€60.2M
Capital expenditure€106M€102M€80.4M€59.9M€53.6M
Total debtn/a€291M€308M€121M€91.5M

Quarterly statements and history in the cockpit →

Virbac competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-20%0%+20%002007XERSELVN6919ADMATLXDYNIOVADNLIRUBICONIRON2228ABCLBAVARLAY6031279688TNGXVIRP.PA6-month return →1-month return →
Up and to the right = strong over both horizons. Virbac is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%20×40×60×002007XERSADMATLX600161RUBICONBAVA603127VIRP.PARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Virbac is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%75%002007XERSADMA600161BAVAVIRP.PAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Virbac is the large dot.

Virbac competitors and peer comparison

Head to head with its named competitors (VIRP.PA vs ZTS vs ELAN vs VETO.PA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Virbac VIRP.PA$3.20B-4%+4%15%16.6×5.8%
Zoetis ZTS$34.8B+7%+1%37%13.8×-2.9%
Elanco Animal Health ELAN$13.3B+28%+12%8%21.5×32.9%
Vetoquinol VETO.PA$1.10B+19%-1%15%15.5×-3.6%
Merck & MRK$340B+23%+5%18%16.4×8.3%
Phibro Animal Health PAHC$1.44B+5%+10%13%9.9×-6.4%

How Virbac compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Virbac against its 20 peers (data as of 18 Nov 2026)
MeasureVIRP.PAPeer medianRank in peer set
1-month return+0.9%-5.6%5th highest of 21
6-month return-4.3%+5.5%8th lowest of 21
Distance from 52-week high-10.7%-29.3%3rd highest of 21
Revenue growth (TTM)+4.3%+8.9%8th lowest of 17
Operating margin15.1%-3.2%6th highest of 17
Forward P/E16.6×31.3×2nd cheapest of 9
Growth the price implies (Req g, 7 yrs)5.8%2.2%3rd most demanding of 6
Growth delivered (Del g)+9.4%+27.4%2nd lowest of 6
Hurdle (Req g minus delivered)-3.6 pp-31.7 pp2nd most demanding of 6
ROIC minus cost of capital+3.4 pp-9.4 pp4th highest of 16
EV / EBITDA10.8×53.7×2nd cheapest of 6
Net debt / EBITDA0.7×1.0×4th least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Virbac VIRP.PAFrance$3.20B-4%+4%15%16.6×5.8%+9.4%
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%26.7×15.8%-1.8%
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%49.7×29.5%+70.2%
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%n/an/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%16.7×-0.8%+64.6%
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%34.5×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%n/an/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%n/an/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%33.1×2.2%+12.5%
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%66.6×n/an/a
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%n/an/an/a
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%n/an/an/a
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%16.6×-4.3%+27.4%
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%n/an/an/a
Joinn Laboratories (China) 603127.SSChina$3.67B-6%+12%-4%29.4×n/an/a
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%n/an/an/a
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
Sunshine Lake Pharma 6887.HKHong Kong$2.72B-7%+20%-3%n/an/an/a

Questions

Who are Virbac's main competitors?
Named competitors: Zoetis (ZTS), Elanco Animal Health (ELAN), Boehringer Ingelheim (private or unlisted), Vetoquinol (VETO.PA), Merck & Co (MSD Animal Health) (MRK), Phibro Animal Health (PAHC). The cockpit's measured peer set (industry) also includes Hualan Biological Engineering (002007.SZ), Xeris Biopharma (XERS), Enliven Therapeutics (ELVN), Caliway Biopharmaceuticals (6919.TW), ADMA Biologics (ADMA), Telix Pharmaceuticals (TLX.AX).
Is Virbac expensive compared with its peers?
On forward p/e it trades at 16.6× against a peer median of 31.3×, 2nd cheapest of 9 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has Virbac stock performed?
Over six months to 18 Nov 2026 the shares returned -4.3% against +5.5% for the median peer; over one year -2.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.